Full Text View
Tabular View
Study Results
Related Studies
Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines
This study is ongoing, but not recruiting participants.
Study NCT00891176   Information provided by GlaxoSmithKline

First Received on April 30, 2009.   Last Updated on November 21, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Pneumococcal Disease
Hepatitis B Disease
Persistence of Immunogenicity
Meningococcal Disease
Additional conditions recognized in this trial
Hepatitis
Hepatitis A
Hepatitis B
Influenza, Human
Meningococcal Infections
More general conditions related to this trial
Bacterial Infections
Digestive System Diseases
DNA Virus Infections
Enterovirus Infections
Gram-Negative Bacterial Infections
Hepadnaviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Neisseriaceae Infections
Orthomyxoviridae Infections
Picornaviridae Infections
Respiratory Tract Diseases
Respiratory Tract Infections
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
MenitorixTM
PrevenarTM
MeningitecTM
NeisVac-CTM
InfanrixTM hexa
InfanrixTM penta
InfanrixTM IPV/Hib
InfanrixTM IPV
Additional drug interventions recognized in this trial
Antibodies
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services